Dominick Colangelo
Chief Executive Officer bij VERICEL CORPORATION
Vermogen: 10 M $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Dominick Colangelo
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 29 | |
| Public Company | Biotechnology | 18 | |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.
17
| Private Company | Miscellaneous Commercial Services | 17 |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.
3
| Subsidiary | Medical Specialties | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Dominick Colangelo via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| HERON THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CAMBREX CORPORATION | Pharmaceuticals: Generic | Chief Executive Officer Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| WINDTREE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| AFFYMETRIX, INC. | Medical Specialties | Director/Board Member Founder | |
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Corporate Officer/Principal | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| DELCATH SYSTEMS, INC. | Medical Specialties | Chief Executive Officer Director of Finance/CFO | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal General Counsel General Counsel Corporate Officer/Principal Corporate Officer/Principal | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director/Board Member Chairman | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| Michigan State University | College/University | Undergraduate Degree Undergraduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree | |
| Boston University | College/University | Corporate Officer/Principal Masters Business Admin | |
Paul Capital Partners LP
 Paul Capital Partners LP Investment ManagersFinance Founded in 1991 by Philip Paul, Paul Capital Partners LP is a private equity firm located in San Francisco with additional offices in New York City, Hong Kong, London, Paris and São Paulo. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| University of London | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Tufts University | College/University | Corporate Officer/Principal Undergraduate Degree | |
| US Military Academy | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Florida | College/University | Undergraduate Degree Masters Business Admin | |
| University of Illinois | College/University | Doctorate Degree Graduate Degree | |
| University of Maryland | College/University | Undergraduate Degree Masters Business Admin | |
| University of Michigan | College/University | Corporate Officer/Principal Doctorate Degree | |
| OCATA THERAPEUTICS INC | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| Parke, Davis & Co. LLC | Chairman Chief Tech/Sci/R&D Officer | ||
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Chief Operating Officer General Counsel | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| Tufts University School of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| Sanofi Corp. | Corporate Officer/Principal Corporate Officer/Principal | ||
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| SYNLOGIC, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Combined Therapeutics, Inc.
 Combined Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Founder Founder |
Statistieken
Internationaal
| Verenigde Staten | 46 |
| Verenigd Koninkrijk | 3 |
| Denemarken | 2 |
| Zwitserland | 2 |
| Canada | 2 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 15 |
| Commercial Services | 5 |
| Finance | 3 |
Operationeel
| Director/Board Member | 316 |
| Corporate Officer/Principal | 148 |
| Independent Dir/Board Member | 109 |
| Director of Finance/CFO | 69 |
| Chief Executive Officer | 58 |
Sterkste connecties
| Insiders | |
|---|---|
| Daniel Geffken | 53 |
| Ed Mathers Mathers | 47 |
| David Singer | 28 |
| Paul Wotton | 27 |
| Walter Flamenbaum | 26 |
| Steven Gilman | 25 |
| Michael Heffernan | 23 |
| Anne VanLent | 23 |
| Vernon R. Loucks | 22 |
| William J. Rutter | 22 |
| Gregory Brown | 22 |
| Pamela Kirby | 22 |
| John Leone | 21 |
| David J. Clark | 21 |
| David Meeker | 19 |
- Beurs
- Insiders
- Dominick Colangelo
- Bedrijfsconnecties
